Müssle, B.
Kirchberg, J.
Buck, N.
Radulova-Mauersberger, O.
Stange, D.
Richter, T.
Müller-Stich, B.
Klotz, R.
Larmann, J.
Korn, S.
Klimova, A.
Grählert, X.
Trips, E.
Weitz, J.
Welsch, T.
Funding for this research was provided by:
Heidelberger Zentrum für Personalisierte Onkologie Deutsches Krebsforschungszentrum In Der Helmholtz-Gemeinschaft (DD04-NCTC-Respect, HD02-NCTC-Respect)
Technische Universität Dresden
Article History
Received: 27 December 2022
Accepted: 9 March 2023
First Online: 2 May 2023
Declarations
:
: The RESPECT trial is conducted in line with the Declaration of Helsinki. The study protocol was approved by the local Ethical Committee at TU Dresden, Germany (decision number BO-EK-77022021). All patients must be informed about the trial and give written informed consent. We will/have to obtain(ed) informed consent from all participants in the study.
: The final results will be published in a peer-reviewed journal. Furthermore, the results will be presented at appropriate national and international conferences. The datasets analysed during the current study and statistical code are available from the corresponding author upon reasonable request as the full protocol.Furthermore, any data required to support the protocol can be supplied on request.
: The authors declare that they have no competing interests.